Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHRM3 | P20309 | 1/20 | 0.30 |
| ▸ | PDE4A | P27815 | 1/20 | 0.30 |
| ▸ | PDE4B | Q07343 | 1/20 | 0.30 |
| ▸ | PDE4C | Q08493 | 1/20 | 0.30 |
| ▸ | PDE4D | Q08499 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13054400 | 0.84 | — | — | |
| SCHEMBL10345555 | 0.82 | ADORA2A (0.30) | — | |
| SCHEMBL11802553 | 0.79 | HRH4 (0.34) | — | |
| SCHEMBL12904537 | 0.79 | KDM5B (0.33) | — | |
| SCHEMBL19523211 | 0.78 | HTT (0.32) | — | |
| SCHEMBL2611024 | 0.77 | HRH4 (0.34) | — | |
| SCHEMBL26833487 | 0.77 | — | — | |
| SCHEMBL12931233 | 0.73 | HRH4 (0.30) | — | |
| SCHEMBL2600738 | 0.71 | — | — | |
| SCHEMBL24730493 | 0.71 | KDM5B (0.30) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 39 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240018118-A1 | TRICYCLIC COMPOUNDS TO DEGRADE NEOSUBSTRATES FOR MEDICAL THERAPY | C 4 Therapeutics, Inc. (US) | 2024-01-18 | — | — | US | disclosed |
| WO-2023220137-A1 | PYRAZINE DERIVATIVES AND USES THEREOF | FOGHORN THERAPEUTICS INC. (US) | 2023-11-16 | — | — | WO | disclosed |
| US-11771689-B2 | Cereblon modulators and uses thereof | VIVIDION THERAPEUTICS, INC. (US) | 2023-10-03 | — | — | US | disclosed |
| US-20180194739-A1 | METHODS TO TREAT LYMPHOPLASMACYTIC LYMPHOMA | DANA-FARBER CANCER INSTITUTE, INC. | 2018-07-12 | — | — | US | disclosed |
| US-20180194746-A1 | Compounds For the Treatment of HIV | GILEAD SCIENCES, INC. | 2018-07-12 | — | — | US | disclosed |
| US-20180186780-A1 | METHODS TO TREAT LYMPHOPLASMACYTIC LYMPHOMA | DANA-FARBER CANCER INSTITUTE, INC. (US) | 2018-07-05 | — | — | US | disclosed |
| US-9944619-B2 | Compounds for the treatment of HIV | GILEAD SCIENCES, INC. (US) | 2018-04-17 | — | — | US | disclosed |
| US-9908872-B2 | Methods to treat lymphoplasmacytic lymphoma | DANA-FARBER CANCER INSTITUTE, INC. (US) | 2018-03-06 | — | — | US | disclosed |
| US-9856223-B2 | Methods to treat lymphoplasmacytic lymphoma | DANA-FARBER CANCER INSTITUTE, INC. (US) | 2018-01-02 | — | — | US | disclosed |
| US-9780310-B2 | Heterocyclic compound for organic electroluminescent device and its application | TOSOH CORPORATION (JP) | 2017-10-03 | — | — | US | disclosed |
| US-20120107271-A1 | ETHYNYL-SUBSTITUTED PYRIDINE AND PYRIMIDINE DERIVATIVES AND THEIR USE IN TREATING VIRAL INFECTIONS | MERCK SHARP & DOHME LLC | 2012-05-03 | — | — | US | disclosed |
| US-20120095022-A1 | DERIVATIVES OF 10-AMINO-1,2,3,4-TETRAHYDROPYRIDO[2,1-A]ISOINDOL-6(10BH)-ONES, METHOD FOR PREPARATION THEREOF AND THERAPEUTIC USES THEREOF | UNIVERSITE D'ORLEANS (FR) | 2012-04-19 | — | — | US | disclosed |
| US-20110318305-A1 | SUBSTITUTED PYRIDINE AND PYRIMIDINE DERIVATIVES AND THEIR USE IN TREATING VIRAL INFECTIONS | MERCK SHARP & DOHME LLC | 2011-12-29 | — | — | US | disclosed |
| US-20110286965-A1 | ETHENYL-SUBSTITUTED PYRIDINE AND PYRIMIDINE DERIVATIVES AND THEIR USE IN TREATING VIRAL INFECTIONS | MERCK SHARP & DOHME LLC | 2011-11-24 | — | — | US | disclosed |
| US-20110286964-A1 | AZO-SUBSTITUTED PYRIDINE AND PYRIMIDINE DERIVATIVES AND THEIR USE IN TREATING VIRAL INFECTIONS | MERCK SHARP & DOHME LLC | 2011-11-24 | — | — | US | disclosed |
| US-7998987-B2 | Inhibitors of c-Met and uses thereof | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2011-08-16 | — | — | US | disclosed |
| US-20100190774-A1 | INHIBITORS OF C-MET AND USES THEREOF | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2010-07-29 | — | — | US | disclosed |
| US-7728017-B2 | Inhibitors of c-Met and uses thereof | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2010-06-01 | — | — | US | disclosed |
| US-20080207635-A1 | Heterocyclic compounds useful in the treatment of neoplastic diseases, inflammatory disorders and immunomodulatory disorders | CHEMBRIDGE CORPORATION | 2008-08-28 | — | — | US | disclosed |
| US-20070191369-A1 | Inhibitors of c-Met and uses thereof | VERTEX PHARMACEUTICALS INCORPORATED | 2007-08-16 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (13 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120107271-A1 | ETHYNYL-SUBSTITUTED PYRIDINE AND PYRIMIDINE DERIVATIVES AND THEIR USE IN TREATING VIRAL INFECTIONS | CYP2C9, P2RX3, F12 | CHRM3 387/4885PDE4A 2589/4885PDE4B 3028/4885 |
| US-20180186780-A1 | METHODS TO TREAT LYMPHOPLASMACYTIC LYMPHOMA | IRAK1, IRAK4, IRAK2 | CHRM3 3080/4885PDE4A 3204/4885PDE4B 3358/4885 |
| US-20070191369-A1 | Inhibitors of c-Met and uses thereof | MET, HGF, ABL1 | CHRM3 4174/4885PDE4A 2371/4885PDE4B 2443/4885 |
| US-20110318305-A1 | SUBSTITUTED PYRIDINE AND PYRIMIDINE DERIVATIVES AND THEIR USE IN TREATING VIRAL INFECTIONS | PNP, XDH, PNPO | CHRM3 646/4885PDE4A 1722/4885PDE4B 1951/4885 |
| US-20180194746-A1 | Compounds For the Treatment of HIV | CCR5, NPC1, FURIN | CHRM3 4278/4885PDE4A 2296/4885PDE4B 2206/4885 |
| US-20110286965-A1 | ETHENYL-SUBSTITUTED PYRIDINE AND PYRIMIDINE DERIVATIVES AND THEIR USE IN TREATING VIRAL INFECTIONS | CYP2C9, PNP, UGT1A3 | CHRM3 698/4885PDE4A 2279/4885PDE4B 2656/4885 |
| US-20100190774-A1 | INHIBITORS OF C-MET AND USES THEREOF | MET, HGF, ABL1 | CHRM3 4174/4885PDE4A 2371/4885PDE4B 2443/4885 |
| US-20180194739-A1 | METHODS TO TREAT LYMPHOPLASMACYTIC LYMPHOMA | IRAK1, IRAK4, IRAK2 | CHRM3 3058/4885PDE4A 2984/4885PDE4B 3264/4885 |
| US-11771689-B2 | Cereblon modulators and uses thereof | CRBN, CBFB, CNN2 | CHRM3 900/4885PDE4A 344/4885PDE4B 197/4885 |
| US-20240018118-A1 | TRICYCLIC COMPOUNDS TO DEGRADE NEOSUBSTRATES FOR MEDICAL THERAPY | NFATC1, CTSS, MMP12 | CHRM3 4053/4885PDE4A 2776/4885PDE4B 3400/4885 |
| US-20080207635-A1 | Heterocyclic compounds useful in the treatment of neoplastic diseases, inflammatory disorders and immunomodulatory disorders | LCK, MALT1, MYD88 | CHRM3 3409/4885PDE4A 1469/4885PDE4B 1509/4885 |
| US-20110286964-A1 | AZO-SUBSTITUTED PYRIDINE AND PYRIMIDINE DERIVATIVES AND THEIR USE IN TREATING VIRAL INFECTIONS | XDH, CYP2C9, CYP2C8 | CHRM3 885/4885PDE4A 1344/4885PDE4B 1507/4885 |
| US-20120095022-A1 | DERIVATIVES OF 10-AMINO-1,2,3,4-TETRAHYDROPYRIDO[2,1-A]ISOINDOL-6(10BH)-ONES, METHOD FOR PREPARATION THEREOF AND THERAPEUTIC USES THEREOF | HRH2, HRH1, SULT2A1 | CHRM3 127/4885PDE4A 2957/4885PDE4B 2158/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.